Caspofungin as treatment for Candida glabrata hip infection

被引：25
|
作者：
Lejko-Zupanc, T
Mozina, E
Vrevc, F
机构：
[1] Med Ctr Ljubljana, Dept Infect Dis, Ljubljana 1000, Slovenia
[2] Med Ctr Ljubljana, Inst Radiol, Ljubljana 1000, Slovenia
[3] Med Ctr Ljubljana, Dept Orthopaed Surg, Ljubljana 1000, Slovenia
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2005年 / 25卷 / 03期
关键词：
D O I：
10.1016/j.ijantimicag.2005.01.005
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：273 / 274
页数：2
相关论文
共 50 条
  • [21] Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection
    Klevay, Michael J.
    Horn, David L.
    Neofytos, Dionissios
    Pfaller, Michael A.
    Diekema, Daniel J.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 64 (02) : 152 - 157
  • [22] In Vitro Antifungal Susceptibility of Candida glabrata to Caspofungin and the Presence of FKS Mutations Correlate with Treatment Response in an Immunocompromised Murine Model of Invasive Infection
    Fernandez-Silva, Fabiola
    Lackner, Michaela
    Capilla, Javier
    Mayayo, Emilio
    Sutton, Deanna
    Castanheira, Mariana
    Fothergill, Annette W.
    Lass-Floerl, Cornelia
    Guarro, Josep
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (07) : 3646 - 3649
  • [23] Gluteal Necrotizing Soft Tissue Infection and Hip Osteomyelitis due to Candida Glabrata
    Henry, Reynold
    McGillen, Patrick
    Nassiri, Nima
    Asanad, Kian
    Matsushima, Kazuhide
    Inaba, Kenji
    Clark, Damon
    AMERICAN SURGEON, 2023, 89 (05) : 2101 - 2104
  • [24] In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata
    Oliveira, ER
    Fothergill, AW
    Kirkpatrick, WR
    Coco, BJ
    Patterson, TF
    Redding, SW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3544 - 3545
  • [25] Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata
    Barchiesi, F
    Spreghini, E
    Tomassetti, S
    Arzeni, D
    Giannini, D
    Scalise, G
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 4989 - 4992
  • [26] Microevolution of Candida glabrata ( Nakaseomyces glabrata ) during an infection
    Lopez-Marmolejo, Ana L.
    Hernandez-Chavez, Marco J.
    Gutierrez-Escobedo, Guadalupe
    Herrera-Basurto, M. Selene
    Mora-Montes, Hector M.
    Penas, Alejandro De Las
    Castano, Irene
    FUNGAL GENETICS AND BIOLOGY, 2024, 172
  • [27] In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility
    Cota, Jason
    Carden, Michael
    Graybill, John R.
    Najvar, Laura K.
    Burgess, David S.
    Wiederhold, Nathan P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) : 3926 - 3928
  • [28] Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
    Graybill, JR
    Bocanegra, R
    Luther, M
    Fothergill, A
    Rinaldi, MJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 1937 - 1939
  • [29] Candida glabrata infection associated genes
    Kaemmer, P.
    Mielke, K.
    Schulze, S.
    Grosche, L.
    Huenniger, K.
    Fichtner, M.
    Linde, J.
    Shelest, E.
    Guthke, R.
    Kurzai, O.
    Hube, B.
    Brunke, S.
    MYCOSES, 2015, 58 : 44 - 44
  • [30] AntifungalsDevelopment of flucytosine, caspofungin and azole resistance in Candida glabrata, in a child: case report
    Reactions Weekly, 2010, 1299 (1) : 6 - 6
12345